Cardiovascular Diseases

The centre is conducting studies that target established cardiovascular disease, high cardiovascular risk, and hypertension. Trials aim to test novel agents that may lower cardiovascular events and improve blood‑pressure control.

  • Evaluation of a novel peptide therapy for cardiovascular death reduction
  • Comparison of weekly insulin‑based regimen on cardiovascular outcomes
  • Assessment of lipid‑lowering RNA therapy in severe hypertriglyceridemia

With 25 active trials and a team of 11 investigators, Centrum Badawcze Panaceum is a key hub for cardiovascular innovation in Poland.

Digestive System Diseases

Research includes participants with idiopathic or diabetic gastroparesis. The goal is to determine whether a new oral agent can improve stomach emptying and symptom relief.

  • Phase 2 study of a pro‑kinetic compound in gastroparesis
  • Real‑world evaluation of mobility impact in patients with gastroparesis

The site leverages its clinical infrastructure to generate evidence for digestive health therapies.

Immune System Diseases

A broad portfolio focuses on Sjögren’s syndrome, systemic lupus erythematosus, and ulcerative colitis. Trials assess biologic agents that aim to reduce systemic inflammation and improve patient‑reported outcomes.

  • Study of HZN‑1116 in moderate‑to‑severe Sjögren’s syndrome
  • Evaluation of litifilimab for active systemic lupus erythematosus
  • Long‑term safety of efavaleukin alfa in ulcerative colitis

These investigations reflect the centre’s commitment to advancing immune‑mediated disease treatments.

Musculoskeletal Diseases

The facility is evaluating therapies for knee osteoarthritis and related functional outcomes. One study measures how a topical anti‑inflammatory gel influences daily activity levels using wearable trackers.

  • Real‑world evidence study of Voltaren gel on mobility
  • Assessment of physical activity changes in osteoarthritis patients

By integrating digital health tools, the site explores both symptom relief and quality‑of‑life improvements.

Nutritional and Metabolic Diseases

Ongoing work targets type 2 diabetes, hypertriglyceridemia, and severe hypertriglyceridemia. Trials test RNA‑based therapies and peptide inhibitors designed to lower triglyceride levels and stabilize glycemic control.

  • Plozasiran trials in hypertriglyceridemia populations
  • Comparison of weekly IcoSema versus daily insulin regimens
  • Zilebesiran study for hypertension and cardiovascular risk

The research aligns with the centre’s focus on metabolic risk reduction and patient safety.

Skin and Connective Tissue Diseases

Investigations include atopic dermatitis, chronic urticaria, prurigo nodularis, hidradenitis suppurativa, and discoid lupus erythematosus. The primary aim is to evaluate new topical or systemic agents that can achieve clearer skin and lessen disease burden.

  • Ruxolitinib cream efficacy in prurigo nodularis
  • Methotrexate versus placebo in moderate‑to‑severe atopic dermatitis
  • Eltrekibart trial for moderate‑to‑severe hidradenitis suppurativa
  • Daxdilimab study in primary discoid lupus erythematosus
  • BP11 versus Xolair in chronic spontaneous urticaria

These studies illustrate the centre’s dedication to improving dermatologic outcomes for diverse patient groups.

Immune System Phenomena

Research emphasizes the underlying immune system phenomena that drive autoimmunity. Projects investigate how novel biologics modulate immune signaling pathways in diseases such as Sjögren’s syndrome and lupus.

  • Mechanistic assessment of dazodalibep on systemic manifestations of Sjögren’s syndrome
  • Biomarker analysis in litifilimab-treated systemic lupus erythematosus

By focusing on pathophysiological mechanisms, the site contributes to the scientific understanding of immune dysregulation.

Immune System Processes

Trials target specific immune system processes such as cytokine inhibition and B‑cell modulation. The goal is to determine whether targeted interference can achieve disease remission with favorable safety profiles.

  • Evaluation of tibulizumab for hidradenitis suppurativa lesions
  • Zasocitinib study in moderate‑to‑severe hidradenitis suppurativa
  • Efavaleukin alfa investigation in ulcerative colitis

The centre’s integrated approach bridges basic immunology with clinical outcome measurement.